Government to pay half of nation's health care costs within next decade: study

Share this article:
A new study shows that the government’s contribution to the nation’s healthcare tab, already at 45%, is expected to approach 50% within the next 10 years, The Wall Street Journal reports. Overall health spending in the US is expected to double to $4.1 trillion by 2016, consuming 20% of the nation’s gross domestic product, up from the current 16%, data from the federal study show. By then, the study predicts, the government will be paying 48.7% of the nation’s healthcare bill, up from 38% in 1970 and 40% in 1990. According to the study’s projections, Medicare spending grew by 22% to $418 billion in 2006, up from $342 billion in 2005. The study said the growth would slow to 6.5% this year, due to scheduled cuts in payments to physicians and smaller payment increases to managed care Medicare Advantage plans, which cover other benefits as well as drugs. Drug companies have profited from the drug benefit. In the first seven months of 2006, prescriptions funded by Medicare drug plans accounted for nearly 9% of medicines bought in retail pharmacies, The Journal reported, citing data from prescription data tracking firm Verispan. One of the biggest winners was Bristol-Myers Squibb. Nearly 14% of US retail prescriptions for its drugs, particularly Plavix, were financed by the Medicare drug benefit during that period, according to Verispan. Medicare funded prescriptions accounted for more than 10% of AstraZeneca’s and Merck’s prescriptions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...